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Evolution of H1N1 influenza A outbreaks of the past 100 years is interesting and significantly complex and
details of H1N1 genetic drift remains unknown. Here we investigated the clinical characteristics and
immune cross-reactivity of significant historical H1N1 strains. We infected ferrets with H1N1 strains from
1943, 1947, 1977, 1986, 1999, and 2009 and showed each produced a unique clinical signature. We found
significant cross-reactivity between viruses with similar HA sequences. Interestingly, A/FortMonmouth/1/
1947 antisera cross-reacted with A/USSR/90/1977 virus, thought to be a 1947 resurfaced virus. Importantly,
our immunological data that didn’t show cross-reactivity can be extrapolated to failure of past H1N1
influenza vaccines, ie. 1947, 1986 and 2009. Together, our results help to elucidate H1N1 immuno-genetic
alterations that occurred in the past 100 years and immune responses caused by H1N1 evolution. This work
will facilitate development of future influenza therapeutics and prophylactics such as influenza vaccines.
T
he major challenge in regard to influenza surveillance and management is the propensity of the influenza
virus to mutate, altering its immunogenic properties thereby allowing it to evade immune recognition and
cause disease. Influenza A is classified according to the specific combination of its two surface molecules,
hemagglutinin (HA) (H1 – H17) and neuraminidase (NA) (N1 – N9) isotypes1–3 and its diversity is attributed by
two mechanisms: genetic mutation or by gene reassortment4,5. Typically genetic mutation is responsible for
seasonal influenza outbreaks and the emergence of influenza pandemics is a consequence of gene reassortment
among different strains and subtypes4–6. Since the extensively documented influenza pandemic in 1918–20, there
have been a total of five influenza pandemics that have resulted inmillions of deaths worldwide, where the fatality
rate has reachedmore than 2.5% as in the case of 1918 pandemic5,7. In 1957, H2N2 surfaced and replacedH1N1 in
the human population until 1977 when H1N1 resurfaced, leading to co-circulation of the 2 influenza subtypes.
Compared toH3N28, theH1N1 subtype is believed to have a lower rate of antigenic drift which is associated with a
smaller amount of mutations leading to amino acid changes9. Importantly the evolutionary behaviours of H1N1
and H3N2 are divergent leading to a dynamic and ever changing influenza climate in the human population
where one virus subtype typically dominates over the other8,9. Throughout the 100 year history of H1N1, the
specific clinical parameters and immunogenic response to the genetic drift of H1N1 remains to be clarified.
Subsequent to the 1918 H1N1 pandemic were several H1N1 epidemics occurring from the 1920’s to the late
1950’s9–11 which was followed by a 20 year disappearance and a re-emergence in the 1970’s12. In 1947 a significant
antigenic change transpired in the H1N1 virus creating strain distinct from previous 1943 viruses13. The new
H1N1 virus termed ‘‘A-Prime’’ was relativelymild althoughwidespread (a pseudopandemic) and hypothesized to
be a reassortant from two distinct H1N1 strains9,13,14. An unusual H1N1 virus emerged in 1951 that was associated
with severe disease: also thought to be a reassortant virus with genes from novel viruses and older H1N1 segments
SUBJECT AREAS:
PATHOGENS
INFECTION
VIRAL INFECTION
INFLUENZA VIRUS
Received
8 January 2013
Accepted
5 April 2013
Published
23 April 2013
Correspondence and
requests for materials
should be addressed to
D.J.K. (dkelvin@jidc.
org)
* These authors
contributed equally to
this work.
SCIENTIFIC REPORTS | 3 : 1698 | DOI: 10.1038/srep01698 1
from the 1940’s9. Succeeding a 20 year H1N1 disappearance, two
H1N1 epidemics of interest came about, including the 1977 chil-
dren’s pandemic and a swine flu epidemic in 1976 that was feared
to have pandemic potential and led to a massive public vaccination
strategy14. The 1977 epidemic had limited infectivity to the immu-
nologically naı¨ve younger population (persons ,25 years of age)
which is thought to be due to the similar circulating H1N1 viruses
of the 1950’s14.
In 2009 a substantial change in the H1N1 virus occurred, unlike
previous modifications, which allowed the virus to spread rapidly
throughout the globe and prompted theWHO to declare a pandemic
on 11 June 2009 15. Genomic analysis determined the virus was of
swine origin and contained a triple reassortant of swine, human and
avian influenza A genes16. Unlike previous contemporary seasonal
influenza outbreaks, the 2009 H1N1pdm had age-related disparities
in the frequency and severity of infection where the older age groups
were less susceptible to the disease17,18. Furthermore, these differ-
ences in age-related severity are hypothesized to be due to previous
exposure to older H1N1 viruses with similar antigenic epitopes17,18.
After influenza exposure, the body generates antibodies against
the specific influenza strain it has encountered. Anti-HA production
is often associated with immunity to the same or homologous influ-
enza strains and some antibodies have virus neutralizing ability
blocking viral entry to the host cell1,19. Importantly, previous expo-
sure to influenza viruses influences how the body will respond to a
subsequent influenza infection of the same or different genetic sub-
type20. To date, little is known about the immune and clinical res-
ponse to H1N1 influenza viruses of the past 100 years and how the
H1N1 subtype genetic drift and shift affected immune cross-
reactivity. Previously Nelson et al., conducted a large scale genetic
analysis of 71 H1N1 sequences to determine the evolutionary history
of this virus since 1918 9. In our present study, we investigated the
clinical characteristics and immune cross-reactivity of significant
H1N1 influenza strains in the past 100 years in ferrets to determine
the immunogenicity of important H1N1 viruses. We infected ferrets
with historical H1N1 strains from 1943, 1947, 1977, 1986, 1999, and
2009 and monitored them for a 14-day time course to determine the
clinical picture of each influenza strain infection and immune cross-
reactivity. Our findings clarify the influenza clinical picture of his-
torical H1N1 strains and the help to elucidate the antigenic altera-
tions of H1N1 that occurred in the past 100 years. The work here will
facilitate the understanding of the immune response toward H1N1
and with future work may aid the development of future influenza
therapeutics and anti-viral treatments.
Results
Ferrets Infected with historical H1N1 strains show mild clinical
symptoms. The ferret,Mustela putorius furo, is a superlative animal
model for respiratory infections and the influenza ferret infectome
has recently been published21–29. Ferrets show respiratory illness
similar to humans and clinical features of disease are easily
observed where fevers can persist days following infection of
viruses such as 2009 H1N1pdm influenza21,23,30. As well as fever,
nasal discharge and sneezing can also be observed in animals
infected with influenza viruses21. Although the genetic evolution of
H1N1 viruses between 1918 and 2008 has been studied9, the clinical
features of these viruses have not been previously investigated and
compared including the most recent 2009 H1N1 pandemic virus.
Here we used ferrets to experimentally monitor and compare the
clinical immune responses during infection with human historical
H1N1 influenza strains.
We infected ferrets with six influenza A/H1N1 strains; A/AA/
Marton/43 (Marton/43), A/FortMonmouth/1/1947 (FM/47), A/
USSR/90/1977 (USSR/77), A/Taiwan/1/1986 (Taiwan/86), A/New-
Caledonia/20/1999 (NCal/99), and A/NewYork/18/2009 (NY/09).
These influenza A viruses were chosen due to their emergence and
influence in H1N1 genetic history (Fig. 1, strains used in this study
are marked with an asterisks) as covered in the introduction.
Following infection, ferrets were monitored for body temperature,
weight, inactivity level, sneezing and nasal discharge from each group
were observed daily until Day 14 post-infection (pI). Infection by all
strains produced an increase in temperature; the normal range for
ferret temperature is indicated by the shaded area of each graph23
(Supplementary Fig. S1a). The pandemic H1N1 strain NY/09
induced the greatest fever on Day 2 to a temperature of 104% (of
baseline). NCal/99 and Marton/43 infection also caused a high tem-
perature of 103% frombaseline, which peaked onDay 1 andDay 2 pI,
respectively (Table 1). USSR/77 and Taiwan/86 had moderate fevers
and FM/47 had the smallest increase in temperature reaching only
101% above baseline (Table 1).
Analysis of weight loss showed that animals infected with of all
viruses except pandemic NY/09 were able to recover to original
weight or greater following infection (Supplementary Fig. S1b and
Table 1). NY/09 infected ferrets had the most significant weight loss
compared to normal weight fluctuations (shaded area)23 which
peaked at 91% of baseline weight on Day 6 and Day 7. USSR/77
and NCal/99 reached less than 95% and 95% of baseline weight,
respectively, on Day 2 pI (Table 1). Infection with Taiwan/86 pro-
duced the smallest amount of weight loss and animals infected with
FM/47 did not lose any weight at all (Table 1).
Secondary clinical signs were also measured and analysed for all
infections, including nasal discharge, sneezing, and inactivity level
(Supplementary Table S1). USSR/77 infected ferrets had the highest
amount of nasal discharge and NY/09 ferrets had the greatest
amount of sneezing and lethargy. Taken together, analysis of the
complete clinical signs for each H1N1 strain infection suggested a
unique clinical picture for each strain: NY/09 infection had the most
severe with significant increase in temperature and an unrecovered
Figure 1 | History of H1N1 influenza epidemics and pandemics.
www.nature.com/scientificreports
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weight loss compared to mildest strain, FM/47, which did not pro-
duce any weight loss and only a slight increase in temperature.
Analysis of HA immunogenicity in historical H1N1 strains. The
HA protein, a homotrimeric protein that functions in viral entry into
host cells31, and antibodies reactive toward HA have been associated
with host resistance and a decrease in disease severity32–34. It has been
shown that 60% of antibodies produced during an influenza infec-
tion are reactive toward the HA protein35. After determining
the clinical signatures of ferrets infected with historical and
contemporary H1N1 viruses, we went on to analyze the aspects of
H1N1 HA immunogenicity.
The Hemagglutination Inhibition (HI) assay, is a common assay
used to determine the reactivity and/or amount of antibody to the
HAprotein produced during a viral infection and the cross-reactivity
of antibodies raised toward these specific historically important
H1N1 viruses has not been investigated. To determine the cross-
reactivity produced by infection among the historical and contem-
porary influenza strains, we used the harvested antisera from each
ferret strain infection and performHI assays with our panel of H1N1
viruses; PR/34 (A/PuertoRico/8/1934),Marton/43, FM/47, USSR/77,
Taiwan/86, NCal/99, NY/09 and three antisera raised toward viruses
from previous studies SI/06 (A/SolomonIslands/3/2006), Bris/07 (A/
Brisbane/59/2007), Cal/09 (A/California/07/2009) in the analysis23
(Supplementary Table S2).
Interestingly, ferret anti-sera toward the Marton/43 virus showed
HI with its own virus and with the older PR/34 but not with its
nearest chronological neighbour FM/47 (Fig. 2a). FM/47 and
USSR/77 antisera recognized its respective virus and each other
(Fig. 2b and c). Taiwan/86 and 2009 H1N1pdm (NY/09 or Cal/09)
antisera both only reacted with their respective viruses (Fig. 2d and
h). NCal/99 antisera only showed HI with its own NCal/99 virus
(Fig. 2e). Unexpectedly, the SI/06 and Bris/07 antisera were able to
inhibit the NCal/99 virus (Fig. 2f and g). Furthermore, SI/06 antisera
also cross-reacted with the Bris/07 virus and the Bris/07 antisera
recognized the SI/06 virus. Taken together, these results showed
antigenic cross-reactivity to infection among historical and contem-
poraryH1N1 influenza strains. This data suggested similarities of the
host immune response between Marton/43 and PR/34, FM/47 and
USSR/77, and NCal/99 with both SI/06 and Bris/07 but despairing
responses in infection with Taiwan/86 and Cal/09.
We also analysed the HI ability of WHO control antisera against
our H1N1 virus panel (Supplementary Table S3) and the WHO
control viruses versus the H1N1 panel of antisera (Supplementary
Table S4). Expectedly, NCal/99 and SI/06 both reacted with the
WHO seasonal H1N1 antisera and NY/09 reacted with the 2009
H1N1pdm antisera. As well, HI was seen for only the WHO control
seasonal H1N1 virus with NCal/99, SI/06, and Bris/07 antisera and
the WHO control 2009 H1N1pdm with NY/09 (Supplementary
Table S4). Importantly, no detection was observed for the Tawain/
86 virus and earlier viruses with the WHO H1N1 seasonal control.
Taken together, this work suggested that the WHO seasonal H1N1
antisera is only capable of detecting infection from recent seasonal
H1N1 strains.
We investigated the phylogenetic relationship and sequence homo-
logy of the HA gene among the H1N1 viruses used in this study and
included other strains implicated in important historical H1N1 out-
breaks. The temporal structure of phylogenetic tree was comprised of
3 groups separated by long braches (Fig. 3a). The 1918 pandemic
strains and 2009 pandemic isolates each formed their own distinct
cluster. The middle cluster contained 10 epidemic isolates. Within
this cluster, FM/47 was closer to USSR/77 than Marton/43 which was
more similar to PR/34. The 3 latest strains of seasonal H1N1, NCal/
99, SI/06 and Bris/07, were positioned as a clade which was separated
from the early stains by a long branch and clustal alignment of these
three viruses (Supplementary Fig. S2) showed several amino acid
changes from NCal/99 and conserved between SI/06 and Bris/07:
A3V, T99K, Y111H, K157E, V182A, R224K, W268R, T283N, and
N489D. We calculated the protein homology by using the most vari-
able region of the HA gene (HA135-295) which covers most of the
viral surface and sequence change in this area has a strong impact in
immunogenicity36. We found that 94% and higher homology scores
led to HI cross-reactivity in all the cases. On the other hand, cross-
reactivity with lower homologies of 91-93% may or may not take
place (Fig. 3b). Taken together, our results suggested an important
relationship and cross-reactivity between FM/47 and USSR/77 as well
as the NCal/99, SI/06 and Bris/07 group that can be related to the
genetic HA sequence. Further analysis of other influenza genes may
also be important to the understanding of H1N1 evolution.
Discussion
The H1N1 influenza subtype is a significant viral agent affecting
public health that has been responsible for 3 pandemics and several
influenza epidemics globally. Here we investigated the clinical res-
ponse and subsequent immunogenicity following infection with his-
torically and contemporarily relevant H1N1 strains in ferrets.
Importantly, we showed that infection with each strain produced a
unique clinical signature which may be indicative of disease that
affected humans. We also found significant cross-reactivity between
viruses with similar HA aa sequences which can be extrapolated to
protection or no protection following a subsequent infection with
another H1N1 strain. These results are the first to compare the
Table 1 | Temperature and Weight Summary of H1N1 virus infected ferrets. Clinical signs of infected ferrets were measured daily over 14
days. Temperature andweight were recorded daily until end day and are expressed as percentage relative to the pre-infection level at Day 0
Marton/43 FM/47 USSR/77 Taiwan/86 NCal/99 NY/09
Temperature
Peak Temp 103% 101.4% 102% 101.7% 103.1% 104%
Day – Peak Temp Day 2 Day 1 Day 2 Day 2 Day 1 Day 2
Hypothermic Phase (y/n) No Below 100% but in
normal range
Below 100% but in
normal range
Slight Dip on
Day 3
Slight Dip on
Day 12
Yes
Return to Baseline (y/n) No No Yes Yes No No
Day 14 Temperature 101.3% 99% 100% 100.5% 101% 98%
Weight
Lowest Weight 98% No weight loss 92% 98% 95% 91%
Day – Lowest Weights Day 2 — Day 2 Day 2 Day 2 Day 6 and Day 7
Return to Baseline (y/n) Yes — Yes Yes Yes No
Day Return to Baseline Day 3 — Day 4 Day 3 Day 5 —
www.nature.com/scientificreports
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clinical signs and the antigenic relatedness of systematic infection of
this panel of evolutionary important H1N1 viruses in a single study.
These results add to the understanding of how the immune system
responds to an evolving virus.
In the current study we analyzed the clinical parameters of evolu-
tionary H1N1 strain infection in ferrets which has not been prev-
iously compared experimentally. Our results of the evolutionary
H1N1 strains showed that infection with the FM/47 resulted in the
Figure 2 | Hemagglutination Inhibition (HI) analysis of H1N1 strain antisera shows cross-reactivity toward related strains. Ferrets were infected with
various H1N1 influenza strains Marton/43, FM/47, USSR/77, Taiwan/86, NCal/99, SI/06, Bris/07 and NY/09 and antisera was taken at 15 days pI. The
antisera were used to measure HA specific antibody induction using hemagglutination inhibition assay against an H1N1 virus panel: PR/34, Marton/43,
FM/47, USSR/77, Taiwan/86, NCal/99, SI/06, Bris/07 and NY/09 or Cal/09.
www.nature.com/scientificreports
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mildest clinical disease. Interestingly, historical accounts of the 1947
H1N1 outbreak have indicated the virus to cause mild clinical symp-
toms and have a low death rate14. These records support our findings,
where animals infected with FM/47 had the lowest percent nasal
discharge, mildest fever and was the only virus infection which did
not lead to weight loss. Furthermore, USSR/77 infection produced a
moderate disease comparable to the reports of a mild clinical dis-
ease37. Our analysis of the clinical course of Taiwan/86 infection in
ferrets showed a moderate disease consisting of a mild biphasic
temperature increase and minimal weight loss. These observations
were in agreement with clinical disease reported during the 1986
naval base outbreak of influenza which there was no deaths but
patients described fever, non-productive cough, sore throat and
myalgia38. Furthermore, in accordance with our NY/09 data which
had the most significant temperature fluctuations and weight loss,
analysis by Shrestha and colleagues demonstrated that H1N1pdm
was more severe than the previous circulating seasonal influenza
viruses39.
Figure 3 | Phylogenetic relationship and homology of the influenza A H1N1 HA gene. Phylogenetic relationship and homology among the
hemagglutinin protein from different influenza strains are depicted. Evolutionary relationships among historical influenza H1N1 strains were conducted
in MEGA5 using the Maximum Likelihood method and 500 bootstrap replications (a). Antibody cross-reactivity (determined by HI) among influenza
strains is indicated by using the same colors. The numerical values displayed next to the branches indicate the percentage of bootstrap replicates in which
the associated sequences clustered together. Hemagglutinin protein sequence homology among several influenza strains (b). Influenza strains were
grouped according to the HI cross-reactivity observed in the serum from previously-infected ferrets (groups A through F). Alignments of protein
sequences were performed using the highly variable HA135-295 region, which belongs to the HA-RBD area.
www.nature.com/scientificreports
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The influenza virus was first identified in 1932 and since then the
epidemiology and phylogentic analysis of subsequent influenza
epidemics and pandemics have been extensively investigated9,14,40.
Importantly, our results build on the previous investigations as we
report the immunogenic evolution of the HA protein of significant
pandemic and epidemic strains. The epidemic isolates examined by
our phylogenetic analysis showed the 1918 and H1N1pdm 2009
strains to comprise each their own cluster and the seasonal strains
ranging from 1934 to 2007 to cluster together. As expected by chro-
nological analysis, our results showed Marton/43 to cross-react with
its predecessor PR/34 which was in agreement with the phylogenetic
analysis that placed the HA of Marton/43 close to PR/34 in the tree.
Extensive phylogenetic analysis preformed by Nelson MI and col-
leagues suggested the 1947 strain to be a reassortant from two pre-
viousH1N1 viruses combining the PB1, NA andM segements from a
1943 virus with the PB2, PA, HA, NP and NS segments from an
unknown H1N1 virus9. Furthermore, they showed that the HA1
region of the 1947 HA was significantly different from the HA of
the earlier 1940’s strains9. In accordance with this analysis, our
results showed that the FM/47 antisera did not inhibit hemaggluti-
nationwith the earlier PR/34 andMarton/43 viruses and theMarton/
43 antisera did not cross-react with the FM/47 virus. The inability for
immunity induced by Marton/43 virus infection to target the FM/47
virus compliments the influenza vaccine performance in the human
population of the 1940’s as well as previously published studies41.
Specifically, a related 1943 H1N1 virus strain (A/weiss/43), as well as
A/PR/8/34 and B/Lee/40 were used in the influenza vaccine prepara-
tion which was completely ineffective during the ’47 influenza out-
break14,41. Although FM/47 antisera did not recognize the earlier
H1N1 strains, it did cross-react with the HA molecule of the
USSR/77 virus as did the USSR/77 antisera with the FM/47 virus.
In support of these findings, the 1977 epidemic was thought to be the
resurfacing of the FM/47 strain9. The USSR/77 outbreak was known
as ‘The Children’s Pandemic’ since only persons younger than 26
years old were affected14. During this time, older individuals were
considered primed for the 1977 outbreak strain by previous infec-
tions from the 40’s and 50’s37 which is supported by our immuno-
logical evidence. Together, our results, the phylogenetic analysis and
the epidemiological records suggest the triggering of a unique
immune response following infection with Marton/43 and FM/47
and a similar response from infection with the related strains FM/47
and USSR/77.
In the fall of 1986 a significant outbreak of influenza occurred on a
USNaval Base which was found to be caused by strains that had been
circulating in Asia since the spring of that year38,42-44. Taiwan/86 was
isolated from this outbreak and genomic analysis of its HA have
suggested that the Taiwan/86 virus had evolved from viruses circulat-
ing in the early 1980‘s in Hong Kong45. Furthermore, it has also been
suggested that this virus was the product of a reassortment event that
had occurred between two H1N1 viruses9. Our results showed that
the Taiwan/86 strain shared lower homology to 99, 06 and 07 viruses
seen on our phylogenetic tree. The immunogenic findings showed
antisera produced from ferret infection with Taiwan/86 was not able
to inhibit hemagglutination with the other viruses on our virus panel,
which compliments the literature describing the 1986 strain. The
influenza vaccine in 1986 included the A/Chile/1/83 influenza
strain38. Interestingly, during the 1986 US Naval Base outbreak, the
soldiers who were vaccinated were poorly protected from infection
with Taiwan/198638. Furthermore, it was also shown that antibodies
produced by vaccination with the A/Chile/1/83 vaccine preparation
were not able to provide hemagglutination inhibition toward the
newly arisen Taiwan/86 and Taiwan/86-like viruses44. From this
evidence, it was then recommended that the Taiwan/86 strain be
included in the subsequent influenza monovalent vaccine prepara-
tion42,44. Our findings together with the previous reports on
the Taiwan/86 outbreak suggest that the 1986 viruses were an
antigenically unique group of strains that induced a specific immune
response important when considering the evolution of H1N1
immunity.
It can be argued that the H1N1 virus underwent minor genetic
drift in the 10 year span from 1999 to 2009which can be evidenced by
the consistent inclusion of the NCal/99 in the influenza vaccine
preparation9,46. Our genetic analysis showed the three contemporary
H1N1 seasonal viruses, NCal/99, Bris/07 and SI/06, to be proximal to
each other on the phylogenetic tree with a long separation from the
previous Taiwan/86 virus and in a distinct cluster from the 2009
H1N1 pandemic viruses. Moreover, Bris/07 and SI/06 were closer
to each other than they were to NCal/99. Interestingly, the antisera
generated by infection with NCal/99 did not cross-react with the
other two contemporary seasonal H1N1 viruses although the SI/06
and Bris/07 antisera recognized the NCal/09 virus. These results
suggested there to be an amino acid change in Bris/07 and SI/06
from NCal/99 that may have resulted in a new antigenic site that
was not originally present in NCal/99 strain. To investigate this
contention we generated a clustal alignment of these viruses which
showed numerous amino acid changes between Bris/07 and SI/06
sequences with NCal/99. These results may indicate the gradual yet
still present drift of the H1N1 virus in this time period. As well, the
immunogenic evolution seen in our analysis may question the con-
sistent usage of the NCal/99 virus in influenza vaccine preparations
from 2000–2001 to 2006–2007 9,47.
The most significant emergent in H1N1 history since 1918 ensued
in late spring 2009 and was declared a pandemic shortly after15. The
HA from newly emerged H1N1 virus was identified to be similar to
the HA of viruses isolated from North American swine which had
recent and historical precedence48. This virus was designated 2009
H1N1 pandemic (H1N1pdm) and was shown to be a triple reassor-
tant virus containing genes from swine, human and avian influenza
A viruses16. In our phylogenetic analysis it was clearly evident that the
triple reassortant viruses clustered far from the previously circulating
seasonal H1N1 viruses in agreement with similar alignments.
Furthermore, HI assays performed using ferret antisera produced
raised against the NY/09 H1N1pdm antisera was not able to recog-
nize the HA of any other viruses. These results are supported by
previous published findings that determined the cross-protection
initiated following infection with H1N1pdm which was preceded
by infection with contemporary seasonal H1N1 did not occur
through an HA targeted antibody response20. Interestingly, although
an H1N1 component had been included in the seasonal influenza
vaccine preparations since 1977 49, antigen directed pre-existing
immunity to 2009 H1N1pdm was only detected in the elderly sug-
gesting the majority of the current human population was naı¨ve to
the this novel virus50,51. Cross-reactive antibodies found in the elderly
population suggested that protective immunity was induced from
exposure to an older H1N1 virus with antigenic similarities to
2009 H1N1pdm25,50–52. Our study directly tested the ability of infec-
tion with older H1N1 strains from the years 1943 to 1947 to bind the
HA molecule of the 2009 H1N1pdm virus. Against current hypo-
theses, we found that the immune production of antisera from infec-
tion with viruses originating from the 1940’s were not able to
recognize the HA of the novel pandemic viruses. Likewise, the
H1N1pdm antisera did not detect the panel of viruses ranging from
1934 to 2007. Recently, the effect of priming ferrets with historical
H1N1 viruses on the immune response of secondary infection the
H1N1pdm was described53,54. These studies addressed distinct
immunological questions as our study utilizing a different set of
H1N1 viruses. These priming studies complimented our study as
the historical H1N1 strains used were not the same as ours. The
purpose of the previous studies was to determine protection from
priming infection/infections whereas we queried immune detection,
cross-reactivity and clinical analysis. Importantly, a significant
issue that remains is the affect of age on the outcome of infection/
www.nature.com/scientificreports
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sequential infection with the historical and contemporary viruses.
Historical accounts mention clinical pathology among age groups
but do not have a comprehensive analysis of the comparative
severity14,38,49,55. As well, it is not know how the aging immune system
responds to the evolving influenza virus. Although a protective res-
ponse was seen in priming studies in adult animals, it is not know if
protection of the same magnitude would remain during age related
immunosenescence or if the clinical response in the aged would be
similar as we have shown in this study.
Influenza AH1N1 and Influenza AH3N2 have varying patterns of
antigenic and genetic evolution where specifically H1N1 has a lower
rate of acquired mutations8,9. These evolutionary behaviours are
divergent leading to a dynamic and ever changing influenza climate
in the human population where one Influenza A subtype typically
dominates over the other. Importantly, understanding the interplay
between the H1N1 and H3N2 infection evolution remains a signifi-
cant hurdle in influenza reasearch8,9. Nelson and colleagues investi-
gated the genetic evolution of the H1N1 virus by analyzing the
evolution of the whole virus as well as the individual viral segments
from strains since 1918 9. In this study the authors were able to
identify instances where divergent clades co-circulated as well as
events of intra-H1N1 subtype reassortment9. Previously, Smith and
colleagues compared the antigenic and genetic evolution of the
H3N2 virus from strains originating in 1968 to 2003 and found that
antigenic and genetic evolution showed differing patterns8.
Antigenic evolution was punctuated where the strains formed clus-
ters and genetic change was more even and gradual as time
increased8. Here we sought to elucidate the antigenic evolution of
the H1N1 virus. As with the H3N2 virus8, we found the antigenic
change did not vary evenly by year but instead corresponded to
genetic changes in the HA molecule. These studies are significant
for elucidating the intricacies of influenza evolution as the continu-
ous change of the influenza virus is the greatest challenge to the
management of disease and containment of further outbreaks.
A better understanding of the evolution of the influenza virus
and the interplay between the H3N2 and H1N1 strains will improve
the design of prophylactics such as by guiding vaccine strain selection
for yearly trivalent influenza vaccine or may even give insight to
the development of a universal influenza vaccine. More work is
needed to understand the true nature of influenza virus dynamics
and evolution.
Animal models remain the most appropriate mode for the meth-
odical scientific investigation of human influenza virus pathogenesis
and the testing of influenza prophylactics and therapeutics.
Currently, the ferret is thought to be the most suitable animal model
for respiratory influenza virus infection56 since ferrets are physio-
logically susceptible to wild type influenza viruses due to a similar
respiratory tract and are able to transmit the virus once infected. As
mentioned previously, ferrets display similar clinical disease as
humans following influenza infection which include fever, weight
loss, and sneezing and these positive features have been well dis-
cussed previously21,24,26,30,56. As well, the ferret has been shown to have
similar features as human in regard to IFN pathway function and is
potential model for the study of human IFN-gamma signalling24,57.
Although the ferret is an appropriate model, it is imperative to be
mindful of the disparities between animal models and the nature
human infection to have an accurate assessment of research findings
especially from ferret-influenza studies. During experimental influ-
enza infections in animal models, a specific and known amount of
virus is administered to the animal in a controlled manor, usually by
intranasal inoculation. Modeling the infectious behaviour of a virus
is more predictable when the infection route and dose are controlled.
This is in contrast to natural infection where humans are infected
with an unknown amount of virus in an unknown route, whichmust
be considered when extrapolating results from animal model studies.
Most significantly, ferrets as well as other animal models used in
influenza studies are typically ‘Specific Pathogen Free’ (SPF). In this
case, the ferrets are determined to be influenza free prior to study
initiation. Unlike humans who have been previously exposed to vari-
ous subtypes of influenza viruses, ferrets used in influenza studies are
completely naı¨ve to the virus. The nuances of the immune response
subsequent tomultiple influenza infections, such as the phenomenon
of original antigenic sin58, has only started to be elucidated in the
ferret model53 and much work is still required to have a full under-
standing of the effect of sequential influenza infection on the specific
immune responsemounted. Furthermore, since the influenza virus is
subject to both genetic shift and genetic drift35, the clinical manifes-
tations of sequential virus infections by a virus that undergone mul-
tiple genetic drifts would differ from a response of a virus that had
undergone a significant genetic shift as that of the H1N1 2009 pan-
demic variant.
Influenza virus infection has been thought to plague the human
population for hundreds of years, where symptoms of influenza can
be traced back in the writings of the early Greek cultures to 412 BC40.
As many questions still exist in relation to evolution and emergence
of influenza strains, we analyzed the immunological evolution of past
and contemporary influenza viruses. Our results shed light on the
cross-protective immune response toward the HA molecule and
suggest that unique immunity is induced dependent on the HA
sequence. Further work is needed to determine the evolutionary
placement of the 1918 and 1934 virus immunogenicity, as well as
the placement of newly emerging influenza strains. Our results
describing the antigenic evolution of the H1N1 influenza subtype
together with previous work will add to the understanding of the
transcendence of influenza viruses and have implications on the
design of future influenza vaccines.
Methods
Ethics statement. All animal work was conducted in strict accordance with the
Canadian Council of Animal Care (CCAC) guidelines. The University Health
Network (UHN) has certification with the Animals for Research Act (Permit
Number: #0045 and #0085 of the Ontario Ministry of Agriculture, Food and Rural
Affairs) and follows NIH guidelines (OLAW #A5408-01). The animal use protocol
was approved by the Animal Care Committee (ACC) of the UHN. Infections and
subsequent sample collection were performed under 5% isofluorane anesthesia in an
effort to minimize suffering.
Viruses. All viruses, A/PuertoRico/8/1934 (PR/34), A/AA/Marton/43 (Marton/43),
A/FortMonmouth/1/1947 (FM/47), A/USSR/90/1977 (USSR/77), A/Taiwan/1/1986
(Taiwan/86), A/NewCaledonia/20/1999 (NCal/99), and A/NewYork/18/2009 (NY/
09), A/SolomonIslands/3/2006 (SI/06), A/Brisbane/59/2007 (Bris/07), A/California/
07/2009 (Cal/09) are provided by Center for Disease Control and Prevention ((CDC),
Atlanta, GA, USA) or American Type Culture Collection ((ATCC), Manassas, VA,
USA). All virus work was performed in BSL-2 facility.
Infection and ferret monitoring. Maintenance and monitoring of infected ferrets
has been previously described23. Briefly, male ferrets 4–6 months old were bred in an
on-site SPF ferret colony (University Health Network, Toronto, ON, Canada). Prior
to infection, all ferrets were screened for influenza and shown to be seronegative byHI
assay against circulating influenza A and B strains (2010-2011 WHO Influenza
Reagent Kit for Identification of Influenza Isolates (WHO collaborating center for
surveillance, epidemiology and control for influenza infection division)). The kits
contain the circulating influenza strains for the particular year. Prior to infection,
ferrets were randomly selected and pair-housed in cages contained in bioclean
portable laminar-flow clean-room enclosures (Lab Products, Seaford, DE) in the BSL-
2 animal holding area. Baseline body temperature and weight were measured on Day
0 for each animal. Temperatures weremeasured by using a subcutaneous implantable
temperature transponder (BioMedic Data Systems, Inc., Seaford, DE). Upon
infection, ferrets were anesthetized and infected 1mL of virus preparation for each
ferret (0.5mL in each nostril). Ferrets were infected withMarton/43 (N5 12), FM/47
(N 5 10), USSR/77 (N 5 12), Taiwan/86 (N 5 10), NCal/99 (N 5 14), and NY/09
(N5 12). All viruses were used at 105 EID50 except for FM/47 which was infected at
106 EID50 since it was reported to be a milder virus14. Clinical signs (body
temperature, body weight, level of activity, nasal discharge, and sneezing) were
observed daily for 14 days pI. We examined animals at the same time each day for
consistency. Nasal discharge includes crusty nose,mucous, and transparent exudates/
fluids. The scores were calculated from the total animals displaying any nasal
discharge symptom over the total number of animals. The sneezing scores were
calculated from the total animals found sneezing over the total number of animals.
Scores were calculated daily for 14 days and only the peak values for each infection are
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summarized. The inactivity scoring system is based on the reference Reuman et al.,
1989 59 to assess the inactivity level: 0, alert and playful; 0.5, alert but playful only when
stimulated; 1, alert but not playful when stimulated; 2, neither alert nor playful when
stimulated. A relative inactivity index was calculated as follows: S(day 1 to day
14)[score11]n/S(day 1 to day 14)n, where n equals the total number of observations. A
value of 1 was added to each observation unit score so that a score of 0 could be
divided by a denominator, resulting in an index value of 1.0 as the minimum value.
Determination of influenza specific antibody responses. Influenza specific
antibody responses from the uninfected or infected ferrets were measured by HI as
previously described23. Briefly, receptor destroying enzyme ([RDE], Accurate
Chemical & Scientific Corp., Westbury, NY, USA) treated ferret anti-sera was serially
diluted and HI titers were determined by the highest dilution that completely
inhibited influenza hemagglutination (4HAU) of turkey erythrocytes.
Comparative analysis of hemagglutinin sequences. Phylogenetic analysis of
influenza hemagglutinin DNA sequences were conducted in MEGA560 using the
Maximum Likelihood method based on the Tamura-Nei model61, 500 bootstrap
repetitions were performed. To analyze the protein similarity of influenza
hemagglutinin from different H1N1 strains, the aminoacid sequences from the
protein region HA135-295 were aligned using ClustalW262. This region of the HA
protein is part of the hemagglutinin receptor binding domain (HA-RBD), which is
located in the external surface of the virus and it concentrates most of the antigenic
potential of the HA protein36. Amino Acid HA GenBank accession numbers for
Clustal alignment (Supplementary Fig. S2): A/NewCaledonia/20/1999(H1N1)
(AAP34324.1); A/SolomonIslands/3/2006(H1N1) (ABU99109.1); A/Brisbane/59/
2007(H1N1) (ADE28750.1). Amino Acid HA GenBank accession numbers for
homology table (Fig. 3b): A/BrevigMission/1/1918 (AAD17218); A/PuertoRico/8/
1934 (CAA24272); A/AA/Marton/1943-(ABO38054); A/FortMonmouth/1/1947
(ABD77807); A/USSR/90/1977 (ABD95350); A/Taiwan/1/1986 (ABF21274); A/
NewCaledonia/20/1999 (ABF21272); A/SolomonIslands/3/2006 (ABU99109); A/
Brisbane/59/2007 (ACA28844); California/07/2009 (ACP41953); A/NewYork/18/
2009 (ACR67196). GenBank accession numbers for the phylogenetic analysis of HA
DNA sequence (Fig. 3a): A/PR/8/1934 (V01088); A/BrevigMission/1/1918
(AF116575); A/South Carolina/1/1918 (AF117241); A/AA/Marton/1943 (CY02028);
A/FortMonmouth/1/1947 (CY009612); A/USSR/90/1977 (CY010372); A/Taiwan/
01/1986 (DQ508873); A/NewCaledonia/20/1999 (DQ508857); A/SolomonIslands/3/
2006 (EU124177); A/Brisbane/59/2007 (CY030230); A/California/07/2009
(FJ966974); A/NewYork/18/2009 (GQ232064).
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